

KIDNEY CANCER RESEARCH SUMMIT 2019

A Focus on Translational Research Fueled by DOD KCRP Funding
September 12-13, 2019

Collaborations in Kidney Cancer Research
**Renal Task Force: Trial Focus on Small Renal Masses (SRM) and related
Clinical Trials Planning Meeting**
January 23-24 , 2020 Bethesda



KidneyCAN

Clinical Trials Planning Meeting (CTPM)
January 23-24, 2020
Bethesda

**Improving the Management of Small Renal Masses (SRMs)
and Early Stage RCC**


Renal Cancer Task Force
Jan Dutcher, Sabina Signoretti, Michael Jewett

GU Steering Committee

Scope of the Proposed Renal Cancer CTPM

- **Clinical problem:** Overdiagnosis and excessive treatment of incidentally discovered small renal masses (SRMs)
 - SRM: Tumors ≤ 4 cm, 48-66% of new RCC
- **SEER:** Observed incidence of kidney cancer has roughly doubled since the advent of computed tomography, while mortality has remained stable.
- The combination of rising incidence and stable mortality is indicative of overdiagnosis

Figure 1. Kidney Cancer Incidence and Mortality in the United States From 1975 to 2014



Meeting Goals/Objectives

Goal: To foster clinical trials that address the gaps in the evidence based clinical management of early stage kidney cancer with the focus on SRM including patient quality of life and burdens of disease

Objectives:

- Define and prioritize the most important clinically relevant **questions/unmet needs in the management of SRM**
- Define the relevant disease specific **endpoints** for trials
- Explore relevant **lessons learned** from study of other early stage cancers and **barriers** to conducting studies of localized kidney cancer
- Understand current and potential **funding sources**
- **Design one or more clinical trials** of management SRM and related diseases

Meeting Outcomes

Clinical trial(s) in **SRMs** with imaging and molecular biomarker correlates

- Biomarkers, Imaging and RTB pre-treatment
- Treatment alternatives including AS
- Impact imaging, economics, patients
- Need to identify funding source

One or more published reports:

- unmet needs as roadmap for trial design
- novel endpoints

Meeting Logistics

- Length of CTPM (1.5 days) January 23 (Thursday), 24 am
- Number of supported attendees: 44
- Areas of expertise
 - Urological surgery:
 - Radiology: Advanced imaging expertise, ECOG-ACRIN, CIP
 - Pathology with tissue collection and biomarker focus
 - Biostatistics—endpoint and biomarker focus
 - Radiation oncology: Interest in SRS, thermal ablation
 - Medical oncology: Common consult for SRMs
 - Divisions Programs NCI, NIDDK, other
- Proposed location: NIH Campus